Xing Chen et al. report that IL-17, a proinflammatory cytokine widely associated with poor prognosis in solid tumors, drives the therapeutic failure of anti–PD-L1. https://t.co/F2ylfKTW9m
From our #Cancer#Immunotherapy collection: https://t.co/vZLDRiauiJ
#SITC22
Early results from phase I ARROS-1 trial: NVL-520 in #ROS1 by Dr. @alexdrilon at #ENA2022. This novel ROS1 inhibitor is designed to avoid #NTRK (and TRK-related toxicities, which often limit dose intensity). Studied in a heavily pretreated population (71% with ≥2 TKIs and chemo)
Updates to CKB CORE and BOOST 👏! We've made some changes to improve search performance and enhance the search results for "Explore by Variant"! Check out this screenshot for--> #BRAFV600E in CKB CORE #CancerResearch#genomics#precisionmedicine
CKB CORE users--> the next quarterly update to the gene list is now available! This quarter's theme is the tumor suppressor genes! https://t.co/xFBnGRLDpw #cancerresearch#genomics
Check out our new publication: Remotely Guided Immunobots Engaged in Anti-Tumorigenic Phenotypes for Targeted Cancer Immunotherapy- where we convert live macrophages into robots for targeted immunoengineering.
https://t.co/4knQxWieIf
@NihalOlcay@metin_sitti@MayoClinic@MPI_IS
"Scientists are developing numerous approaches to make [cancer] immunotherapy safer, including drafting different immune cells, like the awesomely-named natural killer cells.
Another option is Calibr’s off switch."
https://t.co/pK7F6GxmJW
Our recently updated summary of advances in #BreastCancer research highlights clinical advances that may soon translate into improved care as well as findings from recent studies. Check it out! https://t.co/WXPSd434K2 #BCSM
Interesting study highlighting a new potential mechanism for resistance to immunotherapy -->cancer cells hiding within one another- "transient cell-in-cell structures" #immunotherapy#precisiononcology#CancerResearch https://t.co/lrq3tn5QNe
Did you know a large portion of the evidence in CKB is #preclinical? Learn more about the types of preclinical data available in CKB in our latest blog post! #CancerResearch#genomics#PrecisionMedicine https://t.co/Y4FwGZAIKB
Intriguing discussion of OMICS behind the #HER2low breast cancer by @prat_aleix at #ESMO22
✅Luminal A/B subtypes enriched in HER2Low vs HER2-0
✅Small difference between HER2-0 and HER2Low in ERBB2 mRNA expression
✅New diagnostic assays (mRNA?) needed
@OncoAlert@myESMO